MAPT and Alzheimer disease: Amnestic MCI (aMCI) is considered to clinically correspond to the prodromal stage of typical Alzheimer’s disease (AD) (Dubois et al., 2014; Petersen, 2016) and has been linked to the AD biomarker profile including positive markers for amyloid and tau pathology (Visser et al., 2009; Wolk et al., 2009).